{"eventGroups":[{"deathsNumAffected":0,"deathsNumAtRisk":3,"description":"Cohort 1: Participants received 25 mg Azacitidine sub-cutaneously, and 200 mg/m\\^2 Temozolomide orally; both once a day on Days 1 - 5 of a 28-day cycle.","id":"EG000","otherNumAffected":0,"otherNumAtRisk":3,"seriousNumAffected":0,"seriousNumAtRisk":3,"title":"Azacitidine 25 mg"},{"deathsNumAffected":0,"deathsNumAtRisk":3,"description":"Cohort 2: Participants received 50 mg Azacitidine sub-cutaneously, and 200 mg/m\\^2 Temozolomide orally; both once a day on Days 1 - 5 of a 28-day cycle.","id":"EG001","otherNumAffected":0,"otherNumAtRisk":3,"seriousNumAffected":0,"seriousNumAtRisk":3,"title":"Azacitidine 50 mg"},{"deathsNumAffected":15,"deathsNumAtRisk":17,"description":"Cohort 3: Participants received 75 mg Azacitidine sub-cutaneously, and 200 mg/m\\^2 Temozolomide orally; both once a day on Days 1 - 5 of a 28-day cycle.","id":"EG002","otherNumAffected":0,"otherNumAtRisk":17,"seriousNumAffected":15,"seriousNumAtRisk":17,"title":"Azacitidine 75 mg"}],"frequencyThreshold":"5","seriousEvents":[{"assessmentType":"NON_SYSTEMATIC_ASSESSMENT","organSystem":"General disorders","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":3},{"groupId":"EG002","numAffected":15,"numAtRisk":17}],"term":"Death due to progression of disease"}],"timeFrame":"up to 59 months after enrollment"}